The National Institutes of Health (NIH), through the National Institute of Allergy and Infectious Diseases (NIAID), has announced a new funding opportunity (NOFO) aimed at supporting the development of comprehensive product development strategies for next-generation HIV treatments, associated comorbidities, coinfections, and preventive measures. The R34 Planning Grant allows applicants to strategically plan before submitting Investigational New Drug (IND) applications to the FDA. The opportunity is expected to generate 2-3 awards totaling $1,000,000 for fiscal year 2025, with a maximum budget of $225,000 per year for each project, limited to a one-year period. Applicants must demonstrate multidisciplinary expertise, including involvement from business and clinical experts to develop effective IND-directed strategies. Key dates include the opening date for applications on February 13, 2024, with a submission deadline on December 4, 2024. Specific eligibility criteria encompass a wide range of organizations, including higher education institutions, nonprofits, and for-profit entities. Applications must comply with detailed submission guidelines, including addressing the NIH Data Management and Sharing Policy. Proposals should articulate clear objectives and the strategic alignment of preclinical and clinical activities to promote successful product development and facilitate interactions with potential investors and funding agencies. This NOFO highlights NIH's commitment to advancing research in HIV treatment and prevention.